In plain words

Three small trials gave people NMN for several weeks and found no change in liver blood tests. Three analyses that combined studies, which may include those same trials, disagree: two found no change and one found lower levels of one liver enzyme, ALT.

The short answer

The three randomized trials on this page all found no effect on liver tests: 1250 mg a day for up to 4 weeks in 31 people (Fukamizu, 2022), 250 mg a day for 12 weeks in 34 people (Katayoshi, 2023), and 250 mg a day for 12 weeks in older men, with no n in the ledger (Igarashi, 2022). Pooled estimates that may include these trials split: Chen (2024) and Yang (2026) found no difference, while Wang (2025) found lower ALT in 412 people, with no dose or duration in the ledger. Certainty is low, because the trials are small and short.

The 60-second version

Every study in the video is listed below, with its quote.

Watch on YouTube

Where the evidence sits

Lower liver enzymes

◪ Pooled analysis, Wang et al., 2025 · may overlap studies counted here

No change in liver tests

■ Randomized trial, Fukamizu et al., 2022 · 31 people · up to 4 weeks
■ Randomized trial, Igarashi et al., 2022 · ledger has no n
■ Randomized trial, Katayoshi et al., 2023 · 34 people · 12 weeks
◪ Pooled analysis, Chen et al., 2024 · may overlap studies counted here
◪ Pooled analysis, Yang et al., 2026 · may overlap studies counted here

■ measured by the source's own study · ◪ pooled analysis, may overlap studies counted here · □ reported, reviewed or argued, no new data

Evidence weight6262 / 100?

Who says what

SourceFindingDesignPeopleDose and lengthFunding and independence
Fukamizu et al., 2022No liver damageRandomized trial311250 mg a day, up to 4 weeksNot in ledger
Igarashi et al., 2022Liver enzymes no different from placeboRandomized, placebo-controlledHealthy older men, n not in ledger250 mg a day, 12 weeksNot in ledger
Katayoshi et al., 2023No change in blood chemistryRandomized trial34250 mg a day, 12 weeksNot in ledger
Chen et al., 2024No difference in AST, ALT, ALPMeta-analysis of 6 studiesNot in ledgerNot in ledgerNot in ledger
Wang et al., 2025Lower ALTMeta-analysis412Not in ledgerNot in ledger
Yang et al., 2026No change in AST or ALTMeta-analysis of 10 comparisons330Not in ledgerNot in ledger
Fukamizu et al., 2022

No liver damage

Design
Randomized trial
People
31
Dose and length
1250 mg a day, up to 4 weeks
Funding
Not in ledger
Igarashi et al., 2022

Liver enzymes no different from placebo

Design
Randomized, placebo-controlled
People
Healthy older men, n not in ledger
Dose and length
250 mg a day, 12 weeks
Funding
Not in ledger
Katayoshi et al., 2023

No change in blood chemistry

Design
Randomized trial
People
34
Dose and length
250 mg a day, 12 weeks
Funding
Not in ledger
Chen et al., 2024

No difference in AST, ALT, ALP

Design
Meta-analysis of 6 studies
People
Not in ledger
Dose and length
Not in ledger
Funding
Not in ledger
Wang et al., 2025

Lower ALT

Design
Meta-analysis
People
412
Dose and length
Not in ledger
Funding
Not in ledger
Yang et al., 2026

No change in AST or ALT

Design
Meta-analysis of 10 comparisons
People
330
Dose and length
Not in ledger
Funding
Not in ledger

Did liver enzymes change in the trials?

Fukamizu and colleagues (2022) gave 31 people 1250 mg of NMN once a day for up to 4 weeks and looked for liver damage (hepatotoxicity). They concluded that NMN

can be administered orally to humans at doses 1250 mg once daily for up to 4 weeks without causing hepatotoxicity and vasodilative flushing

Igarashi and colleagues (2022) gave healthy older men 250 mg a day or a placebo for 12 weeks; the ledger has no n for this trial. They compared the two groups:

No significant difference was observed between the NMN and placebo groups with respect to hematological and blood chemistry parameters, including liver enzymes and renal function markers

Katayoshi and colleagues (2023) found no significant change in blood chemistry in 34 people after 250 mg a day for 12 weeks.

Do the pooled analyses agree on ALT?

Three meta-analyses pooled NMN studies, and each may include the trials above, so none is an extra measurement. Chen and colleagues (2024) found no difference in the liver markers AST, ALT and ALP across 6 studies; the ledger has no n, dose or duration for them. Yang and colleagues (2026) pooled 10 comparisons in 330 people, with no dose or duration in the ledger for these figures:

NMN supplementation did not significantly alter ALT levels: MD = −1.03 U/L, 95% CI −2.51 to 0.44, p = 0.169, I2 = 0%.

Wang and colleagues (2025) reported lower ALT in a pooled estimate that may include the trials above, covering 412 middle-aged and older people, with no dose or duration in the ledger:

NMN had a better effect on ALT (SMD: -0.29 IU/L, 95%CI [-0.55, -0.03] p = 0.028).

Why the sources disagree

The three trials measured people directly and point one way; the split is among pooled estimates that may include those trials. Wang limited its pool to middle-aged and older people and reported a standardized difference, while Yang reported a raw difference in U/L. The trials differ in dose and length, from 250 mg a day for 12 weeks to 1250 mg a day for up to 4 weeks, in groups of 31 and 34 people plus older men with no n in the ledger. The ledger has no funding information for any of the six sources.

What would settle it

An independent, pre-registered randomized trial comparing NMN at 250 mg and 1250 mg a day with placebo for at least 24 weeks in middle-aged and older adults, with ALT, AST and ALP as primary outcomes reported as differences from placebo in U/L. A matching result from a second research group would raise certainty from low to moderate.

How this page was made

The 6 sources are three randomized trials and three meta-analyses, whose pooled estimates may include the trials above, found through a PubMed literature search and chosen because they report liver blood tests in people. Every claim was copied word for word from its source into the Longevity Circle ledger and checked against the original text, and a person approved each one. "Leaning" means the independent trials point mostly one way; certainty follows the GRADE levels used in medical reviews. Drafting was assisted by AI.

Changelog: 23 Sep 2026, first version, 6 sources.